Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/37982
Title: The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.
Authors: 
Keywords: 
Mesh: 
Issue Date: 2018
Citation: Br J Clin Pharmacol.2018 06;(84)6:1156-1169
Abstract: We investigated the effects of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampicin) on the pharmacokinetics of the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib, in patients with advanced non-small cell lung cancer in two Phase I, open-label, two-part clinical studies. Part one of both studies is reported.
PMID: 29381826
URI: https://hdl.handle.net/20.500.12530/37982
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos
Hospitales > H. U. La Paz > Artículos

Files in This Item:
File Description SizeFormat 
PMC5980546.pdf1.33 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.